Navigation Links
MEI Pharma Announces Public Offering Of Common Stock
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

The Company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for its drug candidates, Pracinostat, ME-344 and PWT143, and for other general corporate purposes.

Stifel and Cowen and Company are acting as joint book-runners for the offering.

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered pursuant to a "shelf" registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering is being made only by means of a prospectus supplement and accompanying base prospectus. When available, copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140. An electronic copy of the prospectus supplement and accompanying base prospectus relating to the offering will also be available on the website of the SEC at www.sec.gov.

This release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza (azacitidine) in patients with previously untreated MDS in June 2013. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML who are unsuitable for intensive chemotherapy is expected to initiate in the fall of 2013. MEI Pharma is also developing ME-344, a mitochondrial inhibitor derived from its isoflavone-based technology platform. Results from a first-in-human, single-agent clinical study of ME-344 in patients with refractory solid tumors were presented in October 2013. In September 2013, the Company further expanded its pipeline of drug candidates with the acquisition of PWT143, a highly selective PI3-kinase delta inhibitor. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceuticals Karen OConnor Receives 2013 Cardinal Health Supply Chain Excellence Award
2. CPhI Pharma Awards Showcase Industry Drivers
3. Increasing Affluence and Legislative Reforms are Transforming Polands Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies
4. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
5. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
6. CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
7. Pharmacy Technician Certification Board Names Linda Henson and Rico Powell as 2013 PTCB CPhT of the Year Finalists
8. Mission Pharmacal Launches Aquoral Oral Spray for Dry Mouth
9. Jazz Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 5, 2013
10. Pharmacy Technician Certification Board Names Master Sergeant Jessica Hughes the 2013 PTCB CPhT of the Year
11. HOPA Introduces Scope Of Hematology/Oncology Pharmacy Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
(Date:3/24/2017)... , March 24, 2017 ... to develop sutezolid as effective response to infectious disease ... Alliance and the Medicines Patent Pool (MPP) announced a ... antibiotic drug candidate which demonstrated encouraging results in early ... in combination with other TB drugs and follows the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, ... material, and hazardous and non-hazardous materials announced today the acquisition of privately owned ... will add four additional processing facilities and a vast array of additional technologies, ...
(Date:3/24/2017)... ... 2017 , ... Digital Scientists, a software innovation lab specializing in web design ... Greenville, South Carolina location. The lab has set up shop at the renowned ... with South Carolina clients for years from our office here in Atlanta,” explains Digital ...
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider ... caring for those suffering from the full spectrum of disordered eating, announced today that ... professionals from nearly all 50 states and several countries converged on the Green Valley ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Nursing Society (ONS) wanted to create a communications platform that positions them as ... goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh news, ...
(Date:3/24/2017)... ... ... who like to educate themselves on current issues and who enjoy gaining knowledge on ... to appreciate and love the "Informed" series, hosted by Rob Lowe. A new ... the world. , Running for charity has become a multi-million dollar enterprise ...
Breaking Medicine News(10 mins):